Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Foundayo) is a once-daily oral non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly and Company. It is FDA-approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related health condition.
Foundayo) is a once-daily oral non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly and Company. It is FDA-approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related health condition.